Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Current Drug Metabolism
Title:Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Volume: 15 Issue: 2
Author(s): Vojtech Huser, Samuel G. Johnson, Marc S. Williams, Mary V. Relling, Dan Roden, C. Michael Stein, Rachel F. Tyndale, Jesse J. Swen, Mia Wadelius, Stuart A. Scott, Kristine R. Crews, Otito F. Iwuchukwu, Ming Ta Michael Lee, Kelly E. Caudle, Robert R. Freimuth, Jose A.G. Agundez, Matthias Schwab, Caroline F. Thorn, Katrin Sangkuhl, Ellen M. McDonagh, Li Gong, Michelle Whirl-Carrillo, Daniel J. Muller, James M. Hoffman and Teri E. Klein
Affiliation:
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Export Options
About this article
Cite this article as:
Huser Vojtech, Johnson G. Samuel, Williams S. Marc, Relling V. Mary, Roden Dan, Stein Michael C., Tyndale F. Rachel, Swen J. Jesse, Wadelius Mia, Scott A. Stuart, Crews R. Kristine, Iwuchukwu F. Otito, Michael Lee Ta Ming, Caudle E. Kelly, Freimuth R. Robert, Agundez A.G. Jose, Schwab Matthias, Thorn F. Caroline, Sangkuhl Katrin, McDonagh M. Ellen, Gong Li, Whirl-Carrillo Michelle, Muller J. Daniel, Hoffman M. James and Klein E. Teri, Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process, Current Drug Metabolism 2014; 15 (2) . https://dx.doi.org/10.2174/1389200215666140130124910
DOI https://dx.doi.org/10.2174/1389200215666140130124910 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Biomarkers Postponing Motherhood: A Demographic and Contemporary Issue
Current Women`s Health Reviews Receptor Binding Inhibitor Suppresses Carcinogenesis of Cervical Cancer by Depressing Levels of FSHR and ERβ in Mice
Anti-Cancer Agents in Medicinal Chemistry Commentary [The Mood in the Field of Antidepressant Drug Discovery]
CNS & Neurological Disorders - Drug Targets Advances in Ocular Iontophoresis Research
Recent Patents on Nanomedicine Oxidative stress and myocarditis
Current Pharmaceutical Design A Comparison of Ultrasound and Fluoroscopy-guided Celiac Plexus Neurolysis in Patients with Pancreatic Cancer
Current Cancer Therapy Reviews Function and Regulation of Tumor Necrosis Factor Receptor Type 2
Current Medicinal Chemistry Current and Future of Alzheimer's Therapy with the Best Approach
CNS & Neurological Disorders - Drug Targets Identification of Key mRNAs, miRNAs, and mRNA-miRNA Network Involved in Papillary Thyroid Carcinoma
Current Bioinformatics Functional Neuroimaging of Stimulation by Music Using Positron Emission Tomography
Current Medical Imaging Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness
Current Neuropharmacology Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Therapeutic Strategies To Prevent Neurodegeneration And Promote Regeneration In Multiple Sclerosis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Adenocarcinoma of the Appendix in Elderly: Diagnostic Dilemma
New Emirates Medical Journal Physiological Roles of Neurite Outgrowth Inhibitors in Myelinated Axons of the Central Nervous System – Implications for the Therapeutic Neutralization of Neurite Outgrowth Inhibitors
Current Pharmaceutical Design Aβ Produced as a Fusion to Maltose Binding Protein Can Be Readily Purified and Stably Associates with Copper and Zinc
Protein & Peptide Letters The Role of the MAGUK Protein CASK in Neural Development and Synaptic Function
Current Medicinal Chemistry Are Descending Control Pathways of the Lower Urinary Tract and Pain Overlapping Systems?
Central Nervous System Agents in Medicinal Chemistry Role of the GABAA Receptor in Anxiety: Evidence from animal models, molecular and clinical psychopharmacology, and brain imaging studies
Current Neuropharmacology